Low-dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide-Based Regimen for Prevention of Graft-Versus-host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation for Pediatric Patients with Hematologic Malignancies

Yanlu Du,Ying Zhang,Xiaowei Xu,Yu Cai,Yu Wei,Chongmei Huang,Jun Yang,Huiying Qiu,Jiahua Niu,Kun Zhou,Xinxin Xia,Chang Shen,Yin Tong,Baoxia Dong,Liping Wan,Xianmin Song
DOI: https://doi.org/10.1007/s00277-024-05883-w
2024-01-01
Annals of Hematology
Abstract:The low-dose anti-thymocyte globulin (ATG) plus low-dose post transplantation cyclophosphamide (PTCy) -based (low-dose ATG/PTCy-based) regimen had a promising activity in preventing of graft-versus-host disease (GVHD) in adult patients. However, its efficacy in pediatric patients remain to be defined. Here, we presented the findings from 35 pediatric patients undergoing haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with the new regimen for GVHD prophylaxis. The cumulative incidences (CIs) of grades II-III and III-IV acute GVHD (aGVHD) were 34% (95% CI, 17-48%) and 11% (95% CI, 0-21%) within 180 days post-transplantation, respectively. The CIs of chronic GVHD (cGVHD) and moderate-to-severe cGVHD within 2 years were 26% (95% CI, 7-41%) and 12% (95% CI, 0-25%), respectively. The 2-year probabilities of overall survival, relapse-free survival, and graft-versus-host disease and relapse-free survival were 89% (95% CI, 78-100%), 82% (95% CI, 68-98%) and 59% (95% CI, 43-80%), respectively. The CIs of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation by day 180 were 37% (95% CI, 19-51%) and 20% (95% CI, 6-32%) respectively. These results strongly advocate for the efficacy of the low-dose ATG/PTCy-based regimen as a robust strategy for GVHD prevention in haplo-PBSCT for pediatric patients.
What problem does this paper attempt to address?